Thyroglobulin (Tg) level is one of the well-known factors affecting the outcome of radioactive iodine treatment in differentiated thyroid cancer, though this tumor marker is affected by the thyroid-stimulating hormone (TSH) level. To negate this influence, there is an effort to use the stimulated thyroglobulin/ thyroid-stimulating hormone (sTg/TSH) ratio instead of stimulated thyroglobulin (sTg) level alone. N1b cervical lymph node metastasis is also another factor mentioned in literature. This study aims to demonstrate the significance of these two factors whether they affect the treatment outcome in differentiated thyroid cancer patients who received the first radioactive iodine treatment.
PloS one
Journal Article
English
42607083
Guideline Central and select third party use “cookies” on this website to enhance the user experience.
This technology helps us gather statistical and analytical information to optimize the relevant content for you.
The user also has the option to opt-out which may have an effect on the browsing experience.